- Home
- CEPF vs SLN Comparison
CEPF vs SLN Comparison
Compare CEPF & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEPF | SLN |
|---|---|---|
| Founded | 2021 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 594.9M | 678.0M |
| IPO Year | 2025 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CEPF | SLN |
|---|---|---|
| Price | $10.39 | $13.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $42.60 |
| AVG Volume (30 Days) | 7.7K | ★ 1.6M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $559,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $96.45 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.09 | $4.19 |
| 52 Week High | $10.67 | $17.58 |
Technical Indicators
Market Signals| Indicator | CEPF | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 47.70 | 57.55 |
| Support Level | $10.37 | $5.24 |
| Resistance Level | $10.48 | $17.58 |
| Average True Range (ATR) | 0.04 | 0.97 |
| MACD | -0.01 | -0.14 |
| Stochastic Oscillator | 44.12 | 34.02 |
Price Performance
Historical ComparisonAbout CEPF Cantor Equity Partners IV Inc. Class A Ordinary Shares
Cantor Equity Partners IV Inc is a blank check company.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.